Literature DB >> 35135931

Targeting Inflammation is a Double-Edged Sword. Is PDIA1 A Key?

Tatsuo Shimosawa1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35135931      PMCID: PMC9444801          DOI: 10.5551/jat.ED191

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.394


× No keyword cloud information.
In this issue of Journal of Atherosclerosis and Thrombosis (J Atheroscler Thromb), Aoyama J et al. reported the mechanisms of neutrophils to promote atherosclerosis in which how neutrophils adhere to endothelial cells. They followed their own research in which they revealed that high-fat diet increases CXCL1, which activates peptidylarginine deiminase 4 (PAD4) and causes hypercitrullination of histone H3 in neutrophils. In this research, precise mechanisms of how neutrophils adhere to endothelial cells were not revealed. In the current study , they investigated this unanswered question, and, surprisingly, the mechanism is independent of histone citrullination, but PAD4 citrullinates protein disulfide isomerase A1 (PDIA1) and further activates β2-integrin and promotes F-actin polymerization to induce neutrophil adhesion to endothelial cells. It has been long studied how inflammation induces atherosclerosis. The role of macrophages, monocytes, and neutrophils are studied, and since, Warnatsch et al. reported that cholesterol crystals directly activate neutrophils and promote the release of neutrophil extracellular traps (NET), neutrophil–NET axis has been thought to be a pivotal key in developing atherosclerosis . Further, the recent COVID-19 pandemic increased the attention on NET. Not only that cytokine storm is related to NET and prognosis of infected patients, but also NET-related vascular damages and atherosclerosis might cause long-lasting organ damages in COVID-19 survivors . One of the key molecular mechanisms of NET is the citrullination of histone H3. Citrullinated histone induces intracellular chromatin decondensation, and it is one of the essential components of NET. NET traps bacteria and other foreign organisms, protecting us from infection and inflammation; conversely, it is believed to induce atherosclerosis; therefore, targeting NET or PAD, which is an enzyme for citrullination of histone, would be a potential therapy for atherosclerosis. This idea contains a double-edged sword risk; blocking NET or PAD is beneficial for the vasculature but notoriously increases the risk of severe infection. Aoyama et al. reported that activation of PAD4 under a high-fat diet induces hypercitrullination of histone; also, PDIA1 is a substrate for PAD4 to be citrullinated by broad screening using LC-MS/MS. They mimicked the hypercholesterol diet by using CXCL1 to stimulate neutrophils in vitro. PAD4 is known to be activated by ROS as well. Thus, it is assumed that hypercholesterolemia and other conditions that increase ROS, such as aging, diabetes, and hypertension, are risks for developing atherosclerosis activate PAD4 and PDIA1. They showed that the knockdown or inhibition of PDIA1 successfully decreased the adhesion of neutrophils to endothelial cells by their original and very sophisticated method. Moreover, they added insight into the molecule downstream of PDIA1 to reveal αMβ2-integrin and F-actin ( . It suggests that inhibiting PDIA1 could be a promising preventing target to developing atherosclerosis without compromising the immune system. PDIA1 is an enzyme that can regulate protein folding and various proteins, of which those that contain disulfide bonds are the substrates. Indeed, red wine has the potency to inhibit PDI , and in this case, the down streams are coagulation pathways. We should pay attention to off-target effects and evaluate values when opening new therapeutic doors, especially when targeting enzyme activity. PDIA1 can be a new target to prevent atherosclerosis
  5 in total

1.  Revisiting the mechanistic basis of the French Paradox: Red wine inhibits the activity of protein disulfide isomerase in vitro.

Authors:  Christine N Galinski; Jeffrey I Zwicker; Daniel R Kennedy
Journal:  Thromb Res       Date:  2015-11-07       Impact factor: 3.944

2.  Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis.

Authors:  Annika Warnatsch; Marianna Ioannou; Qian Wang; Venizelos Papayannopoulos
Journal:  Science       Date:  2015-07-16       Impact factor: 47.728

3.  CXCL1-Triggered PAD4 Cytoplasmic Translocation Enhances Neutrophil Adhesion through Citrullination of PDIA1.

Authors:  Jiro Aoyama; Mizuko Osaka; Michiyo Deushi; Shoichi Hosoya; Akihito Ishigami; Taketoshi Maehara; Masayuki Yoshida
Journal:  J Atheroscler Thromb       Date:  2021-12-08       Impact factor: 4.394

4.  High-Fat Diet Enhances Neutrophil Adhesion in LDLR-Null Mice Via Hypercitrullination of Histone H3.

Authors:  Mizuko Osaka; Michiyo Deushi; Jiro Aoyama; Tomoko Funakoshi; Akihito Ishigami; Masayuki Yoshida
Journal:  JACC Basic Transl Sci       Date:  2021-05-19

5.  SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology.

Authors:  Flavio Protasio Veras; Marjorie Cornejo Pontelli; Camila Meirelles Silva; Juliana E Toller-Kawahisa; Mikhael de Lima; Daniele Carvalho Nascimento; Ayda Henriques Schneider; Diego Caetité; Lucas Alves Tavares; Isadora M Paiva; Roberta Rosales; David Colón; Ronaldo Martins; Italo Araujo Castro; Glaucia M Almeida; Maria Isabel Fernandes Lopes; Maíra Nilson Benatti; Letícia Pastorelli Bonjorno; Marcela Cavichioli Giannini; Rodrigo Luppino-Assad; Sérgio Luna Almeida; Fernando Vilar; Rodrigo Santana; Valdes R Bollela; Maria Auxiliadora-Martins; Marcos Borges; Carlos Henrique Miranda; Antônio Pazin-Filho; Luis Lamberti P da Silva; Larissa Dias Cunha; Dario S Zamboni; Felipe Dal-Pizzol; Luiz O Leiria; Li Siyuan; Sabrina Batah; Alexandre Fabro; Thais Mauad; Marisa Dolhnikoff; Amaro Duarte-Neto; Paulo Saldiva; Thiago Mattar Cunha; José Carlos Alves-Filho; Eurico Arruda; Paulo Louzada-Junior; Renê Donizeti Oliveira; Fernando Queiroz Cunha
Journal:  J Exp Med       Date:  2020-12-07       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.